Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying disciplines have shown that these agents exhibit cardiorenal‐protective benefits, retinoprotective benefits, and may aid in weight loss without causing marked hypoglycemia. Therefore, these agents represent an avenue in clinical practice to manage comorbid conditions in the hyperglycemic patient. Because of their multifaceted effects and robust action, SGLT2 inhibitors represent therapy options for providers that not only provide beneficial clinical results but also reduce total patient drug burden.

中文翻译：

---

SGLT2的心脏肾脏保护：心血管结局试验的经验教训。

钠葡萄糖共转运蛋白2（SGLT2）抑制剂是一类主要用于治疗2型糖尿病的药物。然而，这些试剂已显示出提供额外的有益作用。我们将讨论与使用SGLT2抑制剂有关的三个主要主题：非心血管效应，心血管益处和新的临床适应症。跨不同学科的多项临床试验和初步研究表明，这些药物具有心脏肾脏保护作用，视网膜保护作用，并可能有助于减肥而不会引起明显的低血糖症。因此，这些药物代表了在临床实践中管理高血糖患者合并症的途径。由于其多方面的影响和强大的行动，